Observational studyInternational journal of oncology2021
circUBAP2 regulates osteosarcoma progression via the miR‑204‑3p/HMGA2 axis.
Observational study in International journal of oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Appraising clinicopathological and prognostic significance of circular RNA ubiquitin-associated protein 2 in human cancer.World journal of surgical oncology · 2025Pooled it
- DCC-2036 inhibits osteosarcoma via targeting HCK and the PI3K/AKT-mTORC1 axis to promote autophagy.World journal of surgical oncology · 2025Article
- Research progress of circRNAs in bone-related diseases.Frontiers in oncology · 2025Review
- Osteosarcoma in a ceRNET perspective.Journal of biomedical science · 2024Review
- Circ_0003945: an emerging biomarker and therapeutic target for human diseases.Frontiers in oncology · 2024Review
- Nuclear High Mobility Group A2 (HMGA2) Interactome Revealed by Biotin Proximity Labeling.International journal of molecular sciences · 2023Article
- Circular RNAs: typical biomarkers for bone-related diseases.Journal of Zhejiang University. Science. B · 2022Article
- circ‑LRP6 contributes to osteosarcoma progression by regulating the miR‑141‑3p/HDAC4/HMGB1 axis.International journal of oncology · 2022Article
- Circular RNA UBAP2 facilitates the cisplatin resistance of triple-negative breast cancer via microRNA-300/anti-silencing function 1B histone chaperone/PI3K/AKT/mTOR axis.Bioengineered · 2022Article
- Circular RNA circ_UBAP2 facilitates the progression of osteosarcoma by regulating microRNA miR-637/high-mobility group box (HMGB) 2 axis.Bioengineered · 2022Article
- Modulation of immunosuppressive cells and noncoding RNAs as immunotherapy in osteosarcoma.Frontiers in immunology · 2022Review
- Non-coding RNAs as potential biomarkers in osteosarcoma.Frontiers in genetics · 2022Review
- Review
- CircHAS2 promotes the proliferation, migration, and invasion of gastric cancer cells by regulating PPM1E mediated by hsa-miR-944.Cell death & disease · 2021Article
- Long non-coding RNA CASC9/microRNA-590-3p axis participates in lutein-mediated suppression of breast cancer cell proliferation.Oncology letters · 2021Article
- Circular RNAs With Efficacy in PreclinicalCancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circular RNA (circRNA/circ)‑ubiquitin associated protein 2 (UBAP2), a newly recognized circRNA, serves a functional role in several types of tumor, including ovarian cancer, colorectal cancer and osteosarcoma. However, the precise roles and molecular mechanism underlying circUBAP2 in osteosarcoma (OS) are not completely understood. In the present study, the expression levels of circUBAP2, microRNA (miR)‑204‑3p and (HMGA2) were evaluated via reverse transcription‑quantitative PCR in OS tissues and cells. OS cell proliferation, migration, invasion and apoptosis were assessed by performing Cell Counting Kit‑8, Transwell and flow cytometry assays, respectively. HMGA2 protein expression levels were determined via western blotting. Dual‑luciferase reporter assays were performed to verify the interaction between circUBAP2 and miR‑204‑3p, and between miR‑204‑3p and HMGA2. An RNA immunoprecipitation (RIP) assay was conducted to confirm the interaction between circUBAP2 and miR‑204‑3p. The results demonstrated that circUBAP2 expression was significantly upregulated in OS tissues and cell lines compared with paracancerous tissues and hFOB1.19 cells, respectively. In addition, high circUBAP2 expression levels in patients with OS were associated with a lower survival rate compared with lower expression levels in patients with OS. The functional assays revealed that circUBAP2 knockdown significantly inhibited OS cell proliferation, migration and invasion, but increased OS cell apoptosis compared with the small interfering RNA‑negative control (si‑NC) group. The dual‑luciferase reporter and RIP assay results confirmed that circUBAP2 bound to miR‑204‑3p. Moreover, miR‑204‑3p expression was significantly downregulated in OS tissues compared with paracancerous tissues, and miR‑204‑3p expression was negatively correlated with circUBAP2 expression in OS tissues. Collectively, the results demonstrated that miR‑204‑3p was associated with circUBAP2 knockdown‑mediated inhibition of OS cell malignant behavior. Moreover, miR‑204‑3p was also identified as one of the direct targets of HMGA2. Collectively, the results indicated that compared with the si‑NC group, circUBAP2 knockdown significantly inhibited OS cell malignant behavior by binding to miR‑204‑3p, which subsequently regulated HMGA2 expression. Therefore, the present study demonstrated that circUBAP2 expression was upregulated in OS, and circUBAP2 regulated OS cell malignant behavior via the miR‑204‑3p/HMGA2 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.